Search
letermovir (Prevymis)
Indications:
- prophylaxis for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation
Dosage:
- 480 mg PO/IV QD, 240 mg QD if also taking cyclosporine
- initiate between day 0 & day 28 posttransplantation (before or after engraftment) & continue through day 100
Tabs: 240 mg, 480 mg
Injection: 20 mg/mL, vials 12 mL, 24 mL
Adverse effects:
- nausea/vomiting, diarrhea
- edema
- cough
- headache
Drug interactions:
- pimozide
- ergot alkaloids
- pitavastatin or simvastatin with cyclosporine
Mechanism of action:
- inhibits the CMV DNA terminase complex (pUL51, pUL56, & pUL89), thus interferes with viral DNA processing & virion maturation
General
heterocyclic compound, 2 rings
antiviral agent
Database Correlations
PUBCHEM cid=45138674
References
- RxNorm
- Wikipedia: Letermovir
https://en.wikipedia.org/wiki/Letermovir
- Lowes R
Letermovir (Prevymis) Okayed for Stem Cell Transplant Infection.
Medscape. Nov 9, 2017
https://www.medscape.com/viewarticle/888295
- Windle ML.
FDA New Drug and Biologic Approvals -- 2017 Year-in-Review
Medscape - Jan 11, 2018.
https://reference.medscape.com/viewarticle/890871
- U.S. Food and Drug Administration.
Novel Drug Approvals for 2017.
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm
- Marty FM, Ljungman P, Chemaly RF
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-
Cell Transplantation.
N Engl J Med. Dec 6, 2017
PMID: 29211658
http://www.nejm.org/doi/full/10.1056/NEJMoa1706640